Effects of isoflavones in peritoneal dialysis patients

Phase 2

Recruiting

• Conditions: End stage of renal disease.; Chronic kidney disease, stage 5; N18.5

• Registration Number: IRCT20091116002716N4
• Lead Sponsor: ational Nutrition and Food Technology Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Continuous Ambulatory Peritoneal Dialysis for 6 months or more
Body mass index below 35

Exclusion Criteria

infections; inflammatory diseases
liver diseases
past medical history of cancer
receiving glucocorticoid and anti-inflammatory drugs
receiving isoflavone supplements
Constant consumption of soy or foods containing soy in the diet

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum concentrations of glucose. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Enzymatic method.;Serum concentrations of fructoseamine. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of carboxymethyl lysine. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Serum concentrations of pentosidine. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: The enzyme-linked immunosorbent assay (ELISA).;Systolic blood pressure. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: mercury sphygmomanometer.;Diastolic blood pressure. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: mercury sphygmomanometer.